Literature DB >> 15913466

The microbiology of ventilator-associated pneumonia.

David R Park1.   

Abstract

Ventilator-associated pneumonia (VAP) is a common complication of ventilatory support for patients with acute respiratory failure and is associated with increased morbidity, mortality, and costs. Awareness of the microbiology of VAP is essential for selecting optimal antibiotic therapy and improving these outcomes. The specific microbial causes of VAP are many and varied. Most cases of VAP are caused by bacterial pathogens that normally colonize the oropharynx and gut, or that are acquired via transmission by health-care workers from environmental surfaces or from other patients. Common pathogens include Pseudomonas species and other highly resistant Gram-negative bacilli, staphylococci, the Enterobacteriaceae, streptococci, and Haemophilus species. Antibiotic-resistant pathogens such as Pseudomonas and Acinetobacter species and methicillin-resistant strains of Staphylococcus aureus are much more common after prior antibiotic treatment or prolonged hospitalization or mechanical ventilation, and when other risk factors are present. The bacterial pathogens responsible for VAP also vary depending on patient characteristics and in certain clinical circumstances, such as in acute respiratory distress syndrome or following tracheostomy, traumatic injuries, or burns. But these differences appear to be due primarily to the duration of mechanical ventilation and/or degree of prior antibiotic exposure of these patients. The causes of VAP can vary considerably by geographic location (even between units in the same hospital), emphasizing the importance of local epidemiological and microbiological data. Atypical bacteria, viruses, and fungi also have been implicated as causes of VAP, but these pathogens have not been studied systematically and their role is presently unclear. In conclusion, information about the microbiology of VAP serves to guide optimal antibiotic therapy. The risk of antibiotic-resistant pathogens can be estimated using simple clinical features and awareness of local microbiology patterns. The roles of atypical bacterial and nonbacterial pathogens in VAP are incompletely understood and should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913466

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  55 in total

1.  Direct identification of major Gram-negative pathogens in respiratory specimens by respiFISH® HAP Gram (-) Panel, a beacon-based FISH methodology.

Authors:  R Koncan; M Parisato; C Sakarikou; G Stringari; C Fontana; V Favuzzi; M Ligozzi; G Lo Cascio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-29       Impact factor: 3.267

2.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

3.  Aetiological agents of ventilator-associated pneumonia and its resistance pattern - a threat for treatment.

Authors:  Mv Pravin Charles; Joshy M Easow; Noyal M Joseph; M Ravishankar; Shailesh Kumar; Umadevi Sivaraman
Journal:  Australas Med J       Date:  2013-09-30

4.  M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections.

Authors:  Stefan Hagel; Svenja Schmitt; Miriam Kesselmeier; Michael Baier; Tobias Welte; Santiago Ewig; Mathias W Pletz
Journal:  Infection       Date:  2019-01-28       Impact factor: 3.553

5.  Elevated tobramycin concentrations following endotracheal administration in a premature infant.

Authors:  Amanda Howard-Thompson; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2008-04

6.  Targeting bacterial biofilms via surface engineering of gold nanoparticles.

Authors:  Karuna Giri; Laura Rivas Yepes; Bradley Duncan; Praveen Kolumam Parameswaran; Bo Yan; Ying Jiang; Marcela Bilska; Daniel F Moyano; Mike Thompson; Vincent M Rotello; Y S Prakash
Journal:  RSC Adv       Date:  2015-12-01       Impact factor: 3.361

Review 7.  Ventilator-associated pneumonia.

Authors:  Mv Pravin Charles; Arunava Kali; Joshy M Easow; Noyal Maria Joseph; M Ravishankar; Srirangaraj Srinivasan; Shailesh Kumar; Sivaraman Umadevi
Journal:  Australas Med J       Date:  2014-08-31

8.  In vivo detection of endotracheal tube biofilms in intubated critical care patients using catheter-based optical coherence tomography.

Authors:  Roshan Dsouza; Darold R Spillman; Ronit Barkalifa; Guillermo L Monroy; Eric J Chaney; Karen C White; Stephen A Boppart
Journal:  J Biophotonics       Date:  2019-01-22       Impact factor: 3.207

9.  Early-Onset Ventilator-Associated Pneumonia in Patients with Severe Traumatic Brain Injury: Incidence, Risk Factors, and Consequences in Cerebral Oxygenation and Outcome.

Authors:  Pierre Esnault; Cédric Nguyen; Julien Bordes; Erwan D'Aranda; Ambroise Montcriol; Claire Contargyris; Jean Cotte; Philippe Goutorbe; Christophe Joubert; Arnaud Dagain; Henry Boret; Eric Meaudre
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

10.  Outcome of ventilator-associated pneumonia: Impact of antibiotic therapy and other factors.

Authors:  Noyal Mariya Joseph; Sujatha Sistla; Tarun Kumar Dutta; Ashok Shankar Badhe; Desdemona Rasitha; Subhash Chandra Parija
Journal:  Australas Med J       Date:  2012-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.